Is MGC Pharma Sitting on a COVID-19 Cure?

MGC Pharmaceuticals is scheduled to release results from its interim analysis of the double-blind Phase II clinical trials on its anti-inflammatory formula ‘ArtemiC’ on patients with COVID-19 sometime in the next few weeks. What could this mean for investors?

The COVID-19 pandemic has plagued the entirety of 2020 and may continue well into the future. To date, there have been over 18 million confirmed cases, over 687K deaths, and hundreds of thousands of new cases being confirmed every day.

In order to mitigate the spread of the virus, countries, and states are enacting lockdown laws, requiring citizens to maintain a safe distance from one another and to limit travel wherever possible. In some instances, like the case of Victoria most recently, citizens have a curfew and will face penalties for being out beyond it.

As a result of the lockdowns, businesses have been hit hard, creating one of the worst recessions in history, with the United States’ GDP shrinking by a record-high annual rate of 32.9%. Needless to say, the world is desperate for some kind of cure for COVID-19 that will allow countries to get back to business as usual and begin repairing…